US5756283A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for improved production of recombinant adeno-associated viruses for gene therapy
Assignee: University of Pennsylvania
•
Filing: 1995-06-05
•
Granted: 1998-05-26
•
Expires: 2015-06-05
Abstract
Abstract A method for enhancing the efficiency of transduction of a recombinant AAV into a target cell is provided. The target cell is infected with a recombinant adeno-associated virus comprising a selected transgene under the control of regulatory sequences. The infected cell is contacted with an agent which facilitates the conversion of single stranded recombinant virus to its double stranded form. When this conversion occurs in the target cell, enhanced transduction of the recombinant virus into said target cell results. The agent can be a helper virus providing a gene which facilitates the conversion, or an agent to which the infected cell is exposed, which facilitates the conversion. In a similar manner, a novel recombinant AAV is provided which contains the facilitating gene and the transgene. The methods may be performed ex vivo or in vivo.
Inventors
- 👤 James M. Wilson
- 👤 Krishna J. Fisher
- 👤 Guang-Ping Gao
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 21:00
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K48/00; C12N2750/00; C12N2750/00011; C12N2750/14011; C12N2750/14111; C12N2750/14141; C12N2750/14143
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
138 words
A method for enhancing the efficiency of transduction by a recombinant adeno-associated virus (rAAV) comprising the steps of: infecting a target cell with a rAAV essentially free of contamination with helper virus, said rAAV comprising: (a) AAV inverted terminal repeat sequences necessary for transduction; and (b) a selected gene operatively linked to regulatory sequences directing its expression, wherein said gene is flanked by the DNA of (a); and introducing into said target cell an agent which delivers an adenovirus E4 open reading frame 6 (ORF 6) gene product to said target cell, said agent selected from the group consisting of a recombinant virus and a recombinant DNA molecule comprising a DNA sequence operatively linked to regulatory sequences which direct expression of said E4 ORF 6 gene product in said target cell thereby enhancing transduction efficiency of the rAAV.
Claim 2
Independent Claim
138 words
A method for enhancing the efficiency of transduction by a recombinant adeno-associated virus (rAAV) comprising the steps of: infecting a target cell with a rAAV essentially free of contamination with helper virus, said rAAV comprising: (a) AAV inverted terminal repeat sequences necessary for transduction; and (b) a selected gene operatively linked to regulatory sequences directing its expression, wherein said gene is flanked by the DNA of (a); and introducing into said target cell an agent which delivers an adenovirus E4 open reading frame 6 (ORF 6) gene product to said target cell, said agent selected from the group consisting of a recombinant virus and a recombinant DNA molecule comprising a DNA sequence operatively linked to regulatory sequences which direct expression of said E4 ORF 6 gene product in said target cell thereby enhancing transduction efficiency of the rAAV.
Claim 3
Dependent Claim
20 words
The method according to claim 1 wherein said agent further delivers an adenovirus E1 gene product to said target cell.
Claim 4
Dependent Claim
13 words
The method according to claim 1 wherein said agent is a recombinant virus.
Claim 5
Dependent Claim
16 words
The method according to claim 3 wherein said recombinant virus expresses an adenovirus E1 gene product.
Claim 6
Dependent Claim
15 words
The method according to claim 3 or 4 wherein said recombinant virus is an adenovirus.
Claim 7
Dependent Claim
20 words
The method according to claim 3 wherein said recombinant virus expresses an adenovirus E4 gene product consisting of ORF 6.
Claim 8
Dependent Claim
41 words
The method according to claim 1 wherein said DNA molecule further comprises a DNA sequence encoding an adenovirus E1 gene product, said DNA sequence operatively linked to regulatory sequences which direct expression of said E1 gene product in said target cell.
Claim 9
Dependent Claim
29 words
The method according to claim 1 or 8 wherein said regulatory sequences directing expression of said adenovirus E4 gene product and/or said E1 gene product comprise a constitutive promoter.
Claim 10
Dependent Claim
40 words
The method according to claim 1 or 8 wherein said regulatory sequences directing expression of said adenovirus E4 gene product and/or said adenovirus E1 gene product comprise an inducible promoter and wherein said cells are exposed to an inducing agent.
Claim 11
Independent Claim
103 words
A method for enhancing the efficiency of transduction of a target cell by a rAAV comprising the step of infecting said target cell with said rAAV essentially free of contamination with helper virus, said rAAV comprising: (a) AAV inverted terminal repeat sequences necessary for transduction; (b) a selected gene operatively linked to regulatory sequences directing its expression; and (c) an adenovirus E4 gene sequence operatively linked to regulatory sequences which direct expression of an adenovirus E4 ORF 6 gene product, wherein said selected gene and said E4 gene sequence are flanked by the sequences of (a) thereby enhancing transduction efficiency of the rAAV.
Claim 12
Independent Claim
103 words
A method for enhancing the efficiency of transduction of a target cell by a rAAV comprising the step of infecting said target cell with said rAAV essentially free of contamination with helper virus, said rAAV comprising: (a) AAV inverted terminal repeat sequences necessary for transduction; (b) a selected gene operatively linked to regulatory sequences directing its expression; and (c) an adenovirus E4 gene sequence operatively linked to regulatory sequences which direct expression of an adenovirus E4 ORF 6 gene product, wherein said selected gene and said E4 gene sequence are flanked by the sequences of (a) thereby enhancing transduction efficiency of the rAAV.
Claim 13
Dependent Claim
43 words
The method according to claim 10, wherein said rAAV further comprises an adenovirus E1 gene sequence operatively linked to regulatory sequences which direct expression of an adenovirus E1 gene product, said selected, E4 and E1 gene sequences flanked by the sequences of (a).
Claim 14
Dependent Claim
17 words
The method according to claim 10 wherein said E4 gene sequence consists of an ORF 6 sequence.
Claim 15
Dependent Claim
31 words
The method according to claim 11 wherein said regulatory sequences directing expression of said E1 gene product comprise an inducible promoter, and wherein said cell is exposed to an inducing agent.
Claim 16
Dependent Claim
22 words
The method according to claim 11 wherein said regulatory sequences directing expression of said adenovirus E1 gene product comprise a constitutive promoter.
Claim 17
Dependent Claim
34 words
The method according to claim 10 wherein said regulatory sequences directing expression of said adenovirus E4 ORF 6 gene product comprise an inducible promoter, and wherein said cell is exposed to an inducing agent.
Claim 18
Dependent Claim
22 words
The method according to claim 10 wherein said regulatory sequences directing expression of said adenovirus E4 gene product comprise a constitutive promoter.
Claim 19
Dependent Claim
69 words
A recombinant adeno-associated virus (rAAV) comprising: (a) AAV inverted terminal repeats sequences necessary for transduction; (b) a selected gene operatively linked to regulatory sequences directing its expression, (c) an adenovirus E4 gene sequence operatively linked to regulatory sequences which direct expression of an adenovirus E4 open reading frame 6 (ORF 6 ) gene product, said selected gene and said adenovirus E4 gene sequence flanked by the sequences of (a).
Claim 20
Dependent Claim
69 words
A recombinant adeno-associated virus (rAAV) comprising: (a) AAV inverted terminal repeats sequences necessary for transduction; (b) a selected gene operatively linked to regulatory sequences directing its expression, (c) an adenovirus E4 gene sequence operatively linked to regulatory sequences which direct expression of an adenovirus E4 open reading frame 6 (ORF 6 ) gene product, said selected gene and said adenovirus E4 gene sequence flanked by the sequences of (a).
Claim 21
Dependent Claim
16 words
The rAAV according to claim 17 wherein said adenovirus E4 gene sequence consists of ORF 6.
Claim 22
Dependent Claim
22 words
The rAAV according to claim 17 wherein said regulatory sequences directing expression of said adenovirus E4 gene product comprise an inducible promoter.
Claim 23
Dependent Claim
22 words
The rAAV according to claim 17 wherein said regulatory sequences directing expression of said adenovirus E4 gene product comprise a constitutive promoter.
Claim 24
Dependent Claim
39 words
The rAAV according to claim 17 further comprising an adenovirus E1 gene sequence operatively linked to regulatory sequences which direct expression of an E1 gene product, said selected, E4, and E1 gene sequences flanked by the sequences of (a).
Claim 25
Dependent Claim
21 words
The rAAV according to claim 21 wherein said regulatory sequences directing expression of said E1 gene product comprise an inducible promoter.
Claim 26
Dependent Claim
21 words
The rAAV according to claim 21 wherein said regulatory sequences directing expression of said E1 gene product comprise a constitutive promoter.
References Cited (Backward Citations)
US4920209A
Cited
US4797368A
Cited
US5139941A
Cited
WO1991018088A1
Cited
US5173414A
Cited
US5354678A
Cited
US5252479A
Cited
WO1993019191A1
Cited
WO1993024641A2
Cited
WO1994012649A2
Cited
WO1994013788A1
Cited
WO1994017832A1
Cited
WO1994020517A1
Cited
WO1994024299A1
Cited
WO1994026914A1
Cited
WO1994028157A1
Cited
WO1994028152A1
Cited
WO1994028938A1
Cited
WO1995000655A1
Cited
WO1995002697A1
Cited
WO1995006743A2
Cited
WO1995013392A1
Cited
WO1995020671A1
Cited
WO1995027071A2
Cited
WO1995033824A1
Cited
WO1995034671A1
Cited
WO1996013598A2
Cited
WO1996013597A2
Cited
WO1996014061A1
Cited
WO1996018418A1
Cited
WO1996022378A1
Cited
US5622856A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-05-25 | 2001-11-24 | 2002-05-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-05-25 | 2005-11-24 | 2006-05-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-05-25 | 2009-11-24 | 2010-05-26 | $7700.00 | Window Closed / Lapsed |